Betty Pettersen, PhD, DABT

Board-certified Toxicologist with over 30 years of experience in the pharmaceutical industry. Throughout my career, I have served as a nonclinical safety team lead for over 60 teams spanning preclinical development to approval across multiple therapeutic areas, including anti-infectives, internal medicine, immunology & inflammation, neurosciences, rare disease, oncology, centers for therapeutic innovation, and genomic medicine. Additionally, I have experience in co-development projects with other pharmaceutical companies and have prepared numerous INDs, CTAs, and NDAs. As a nonclinical safety expert, I have extensive experience in planning, scheduling, budgeting, designing, conducting, and reporting of exploratory and regulatory (GLP) toxicity studies with small molecules, biologics, and gene therapies(>350). I have led the nonclinical safety assessment of over 60 business development opportunities and provided guidance on risk management of nonclinical safety issues and regulatory hurdles. Throughout my career, I have gained a deep understanding of relevant FDA and ICH guidelines and GLP requirements pertaining to toxicology studies. My knowledge and expertise have allowed me to propose innovative approaches and development processes to expedite portfolio deliverables. I also have experience in portfolio management as an Early Candidate Management Team Leader and Project Manager, as well as staff management. As a Toxicologist with a passion for drug development, I have excellent communication and interpersonal skills. I am skilled in reviewing and interpreting data and formulating conclusions regarding risk to human safety. Overall, my extensive experience and expertise make me a valuable asset to any organization looking to advance their pharmaceutical development initiatives.